We provide a precision-engineered approach to de-risk your research pipeline. By offering modular evaluation services, we enable researchers to transition seamlessly from target validation to functional candidate testing. Whether you are developing bispecific antibodies, small-molecule inhibitors, or engineered macrophage constructs, our platform provides the empirical data required to demonstrate potency and mechanistic engagement. We partner with you to refine your construct, optimize dosing strategies, and validate immune cross-talk in relevant research model systems.

Advanced Innate Immune Evaluation

The CD47-SIRPα signaling axis is a fundamental checkpoint in innate immune surveillance. By acting as a "don't eat me" signal, CD47 prevents macrophage-mediated phagocytosis and supports target cell survival. Mastering the modulation of this axis is essential for researchers aiming to design high-potency immunotherapies. At Creative Biolabs, we specialize in providing the high-resolution, empirical data necessary to evaluate therapeutic candidates targeting this checkpoint. By combining standardized research models with advanced functional assays, we offer a robust foundation for your preclinical studies. Our commitment to scientific excellence ensures that your team receives the precise, actionable insights required to navigate complex immune interactions and successfully advance your discovery programs.

Research-Driven Capabilities

Our specialized platform provides high-throughput, research-grade assays designed to characterize macrophage-tumor interactions, enabling you to validate the efficacy of your therapeutic candidates with high precision and reproducibility.

Access our full scope of services—submit an inquiry for a comprehensive platform review.

Workflow

We employ a systematic, multi-stage development pipeline that transforms target concepts into actionable data. Our workflow is designed for maximum impact and rigorous documentation throughout your research.

Publication

This review examines the CD47-SIRPα axis as a therapeutic target in cutaneous T-cell lymphoma (CTCL). It details current agents, anti-CD47/SIRPα antibodies, SIRPα-Fc fusions, and bispecific antibodies, and their mechanisms. A key limitation of anti-CD47 monoclonal antibodies is the unintended blockade of SIRPγ on T cells, which dampens anti-tumor immunity. The authors propose combination strategies, including checkpoint inhibitors and chemotherapy, to enhance efficacy and overcome the immunosuppressive tumor microenvironment.

Fig.1 Anti‑CD47 mAb promotes tumor phagocytosis but suppresses anti‑tumor T‑cell responses via off‑target inhibition of SIRPα and SIRPγ. ¹

Why Choose Us?

Creative Biolabs stands at the forefront of immuno-oncology, blending decades of rigorous scientific methodology with industrial scalability. Our platform is distinguished by an ability to evaluate innate engulfment potential and downstream immune responses, providing a holistic view of therapeutic efficacy. We de-risk your development pipeline by offering modular services that transition seamlessly from target validation to functional candidate testing. Our researchers utilize standardized models and high-throughput screening to ensure reproducibility and precision. Whether you are developing bispecific antibodies or novel small-molecule inhibitors, our team provides the empirical data required to demonstrate potency and mechanistic engagement.

Optimize your project timeline—contact our project management team to request a detailed scope of work.

FAQs

Q1: Can you evaluate both antibodies and small-molecule inhibitors?

A1: Absolutely. Our platform is agnostic to modality and is designed to characterize any candidate aimed at disrupting the CD47-SIRPα interaction.

Q2: How do you ensure the translation of research results?

A2: We utilize advanced, physiologically relevant tumor microenvironment models that mimic the immunosuppressive barriers often found in complex solid tumors.

Q3: Do you offer engineered macrophage construction?

A3: Yes, we provide full-service construct engineering and efficacy testing, from design to in vitro functional validation.

Customer Review

• Robust Phagocytosis Data
  Using Creative Biolabs’ evaluation service, we obtained highly reproducible phagocytosis data. Their platform’s sensitivity provided the empirical evidence required to advance our lead antibody candidate efficiently. - J. D***
• Enhanced Construct Potency
  The support for engineered macrophages was exceptional. The team helped optimize our constructs, resulting in enhanced functional potency within our experimental solid tumor models. We are very satisfied. - M. S***

Related Services

How to Contact Creative Biolabs

Partner with Creative Biolabs to master the CD47-SIRPα checkpoint. Our specialized services provide the rigorous data needed to accelerate your research. Contact our team to discuss your project today.

Reference

1. Xiao, Amy, and Oleg E. Akilov. "Targeting the CD47-SIRPα Axis: present therapies and the future for cutaneous T-cell lymphoma." Cells 11.22 (2022): 3591. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cells11223591